PWP
CTMX icon

Pursue Wealth Partners’s CytomX Therapeutics CTMX Stock Holding History

Pursue Wealth Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.3K Hold
14,492
– – 0.03% 91
2026
Q1 		$68K Hold
14,492
– – 0.04% 101
2025
Q4 		$62K Hold
14,492
– – 0.03% 104
2025
Q3 		$46.2K Hold
14,492
– – 0.03% 110
2025
Q2 		$32.9K Buy
+14,492
New +$23.4K 0.02% 110

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Pursue Wealth Partners's CTMX Position: Q2 2026 in Review

Pursue Wealth Partners held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 14,492 shares worth $54.3K. The position accounts for 0.03% of the portfolio, ranked #91.

Pursue Wealth Partners first reported a position in CTMX in Q2 2025 and has held it in 5 quarters since. The position peaked at $68K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Pursue Wealth Partners held 14,492 shares of CytomX Therapeutics worth $54.3K as of Q2 2026.
  • Pursue Wealth Partners left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up 0.03% of Pursue Wealth Partners's portfolio in Q2 2026, its #91 holding.
  • Pursue Wealth Partners first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Pursue Wealth Partners's CytomX Therapeutics position peaked at $68K in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Pursue Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.